Furthermore, individuals with high levels of wild–type spike–specific mucosal IgA were shown to be at a lesser risk of subsequent Omicron breakthrough infection [11], and broadly neutralizing IgA antibodies elicited by mucosal tissues from Wuhan COVID-19 convalescent patients were found to potently neutralize Omicron BA.1 and BA.2 infections [12]. This evidence concerns the gene CD79A and COVID-19.